Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell 3Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 4Specimen Handling 3Cyclophosphamide 3Biopsy 3sodium-iodide symporter 2fludarabine 2cemiplimab 2alectinib 2X-Rays 2Stem Cell Transplantation 2Photons 2Nivolumab 2Immunoglobulin G 2Disulfides 2treosulfan 1sargramostim 1ruxolitinib 1repotrectinib 1duvelisib 1brigatinib 1belinostat 1Whole-Body Irradiation 1Vinblastine 1Suspensions 1Standard of Care 1Practice Guidelines as Topic 1Positron-Emission Tomography 1Mycophenolic Acid 1Leukapheresis 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Large-Cell, Anaplastic × 10-propargyl-10-deazaaminopterin × Clear all
NCT06561048 2026-04-08

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Corvus Pharmaceuticals, Inc.

Phase 3 Recruiting
150 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡